TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03693339
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
Study: NCT00530218
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
Study: NCT01606787
Drug: mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
Study: NCT00004160
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02008422
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
Study: NCT02008422
Drug: Gimeracil and Oteracil Potassium Capsule
Normalized name: cytarabine and daunorubicin
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
Study: NCT02008422
Drug: Endostar injection
Normalized name: Menostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
Study: NCT00004160
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004160
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03333317
Drug: Lumicitabine
Normalized name: Lumicitabine
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral administration of lumicitabine.
Study: NCT01095354
Drug: Sodium Chloride Inhalation
Normalized name: Sodium Chloride Inhalation Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum.
Study: NCT02707393
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT02707393
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infusion
Study: NCT02707393
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion
Study: NCT02707393
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT02707393
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion, orally if possible
Study: NCT02707393
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infusion
Study: NCT02838901
Drug: Beet it Beetroot juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
Study: NCT02838901
Drug: Beet It Placebo Beetroot juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
Study: NCT02075047
Drug: ziprasidone oral capsules
Normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
Study: NCT04403243
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
Study: NCT04403243
Drug: Ruxolitinib 5 MG
Normalized name: ruxolitinib 5 MG
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib - 5mg twice a day per os for ten days
Study: NCT04403243
Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab - 300mg subcutaneously singly
Study: NCT00413829
Drug: Intravitreal ranibizumab with photodynamic therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection, photodynamic therapy
Study: NCT02821377
Drug: intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
Study: NCT03397134
Drug: Roluperidone 32 mg
Normalized name: Domperidone
DrugBank: Roluperidone (DB13080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone administered as a single dose once daily
Study: NCT03397134
Drug: Roluperidone 64 mg
Normalized name: Domperidone
DrugBank: Roluperidone (DB13080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone administered as a single dose once daily
Study: NCT02757443
Drug: 5% Glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
Study: NCT03287674
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.
Study: NCT03287674
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
Study: NCT03287674
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
Study: NCT03287674
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
Study: NCT05792644
Drug: crizotinib for rearrangement-negative, high phosphorylated ALK patients
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
Study: NCT01703117
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-22 subjects between the ages of 60-85 will receive study drug.
Study: NCT01342965
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib was supplied as tablets.
Study: NCT04251780
Drug: Drug treatment of Hyperaldosteronism
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
Study: NCT02714881
Drug: certolizumab
Normalized name: certolizumab
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
Study: NCT00554658
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
Study: NCT03691350
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive NRT comprising patch, gum, or lozenge
Study: NCT01646619
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%.
Study: NCT02046070
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules
Study: NCT02046070
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets
Study: NCT01752400
Drug: AUY922
Normalized name: AUY922
DrugBank: AUY922 (DB11881)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02516826
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02516826
Drug: Placebo of Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495064
Drug: Mometasone Furoate Cream
Normalized name: Mometasone Furoate Cream
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
Study: NCT03445728
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
Study: NCT00343863
Drug: palonosetron hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00343863
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally or IV
Study: NCT01064492
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
Study: NCT00343863
Drug: ondansetron hydrochloride
Normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01548612
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
Study: NCT01548612
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of glucose solution 5% for 240 minutes
Study: NCT00052312
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00052312
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01895244
Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
Study: NCT01193166
Drug: paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 78, 117, 156, or 234 mg monthly injection for 12 months
Study: NCT01193166
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: haloperidole
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT01193166
Drug: paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT03747900
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
Study: NCT02124954
Drug: TA-8995
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02124954
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02124954
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00817648
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
Study: NCT00817648
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
Study: NCT05532267
Drug: Ciprofloxacin 750 mg
Normalized name: ciprofloxacin 750 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin
Study: NCT05532267
Drug: Ciproxin 750 mg
Normalized name: Ciproxin 750 MG Oral Tablet
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin
Study: NCT04152434
Drug: Erenumab Auto-Injector
Normalized name: erenumab Auto-Injector
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Assess synergy of add on medication to Erenumab
Study: NCT02148432
Drug: dexmedetomidine infusion rate, 0.5 mcg/kg/hr
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
Study: NCT02148432
Drug: dexmedetomidine infusion rate, 1.0 mcg/kg/hr
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
Study: NCT00236392
Drug: rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457444
Drug: Pollen
Normalized name: Pollen
DrugBank: Ragweed pollen extract (DB05368)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02084238
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
Study: NCT04401839
Drug: Oxytocin IV shot
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
Study: NCT04401839
Drug: Oxytocin IV drip
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
Study: NCT00677755
Drug: mifepristone combined misoprostol
Normalized name: mifepristone, combinations
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
Study: NCT00677755
Drug: misoprostol alone protocol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients were only administered 0.8 mg of misoprostol orally on day 3.
Study: NCT03283397
Drug: INF beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
Study: NCT04041427
Drug: Albendazole Pill
Normalized name: albendazole Pill
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400mg po
Study: NCT00746733
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg capsule
Study: NCT00746733
Drug: Adderall XR (mixed salts amphetamine)
Normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg capsule
Study: NCT03510871
Drug: nivolumab, ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
Study: NCT00086502
Drug: Comparator: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
Study: NCT00086502
Drug: Comparator: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Study: NCT00086502
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
Study: NCT01592617
Drug: S-488410
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
Study: NCT02745717
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
Study: NCT02745717
Drug: Cyclosporine Oral Product
Normalized name: cyclosporine Oral Product
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
Study: NCT02191839
Drug: Alpha 1-Antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01945775
Drug: talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Until progression or unacceptable toxicity develops
Study: NCT00650520
Drug: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT01817790
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nasal spray formulation (200 mcg/day)
Study: NCT03109691
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group 1